


*Development of affordable
glycoconjugate vaccines for
livestock to reduce food cost
and improve food security*



Brendan Wren

London School of Hygiene & Tropical Medicine

Better affordable livestock vaccines means

Improved
food security,
productivity,
nutrition,
sustainability,
And contributes to
one health,
addressing zoonosis,
Etc.



BILL & MELINDA
GATES *foundation*



Glycoconjugate-based vaccines

Polysaccharide-based vaccines produce a T-cell independent immune response with IgM that opsonises bacteria.

To convert to a more favourable T-cell dependent response polysaccharides are often conjugated to proteins

Examples of successful human glycoconjugate vaccines

- 1. *Haemophilus influenzae***
- 2. *Neisseria meningitidis* (except type B)**
- 3. *Streptococcus pneumoniae* (some serotypes)**


Long lasting immunity & suitable for infants and elderly

Billion doses given per year!

Not used for animals?


Traditional chemical conjugation v bioconjugation

Chemical



- **Multistep procedure**
> 300 quality control steps.
- **Expensive**
- **Product often heterologous**

Bioconjugation (PGCT)



↓ **complexity**


↓ **cost**

↑ **flexibility**

The genesis of bacterial glycoengineering


1. Discovery of *Campylobacter* N-linked glycosylation system

(Parkhill *et al.* Nature 2001)




2. Functional transfer of glycosylation system into *E. coli*

(Wacker *et al.* Science 2002)



3. Coupling of capsules and O-antigen to proteins in *E. coli*

(Feldman *et al.* PNAS 2005)




New glycoengineering processes

- Glycan Expression Technology (GET)
- Protein Glycan Coupling Technology (PGCT)
- Glycan Seeking Technology (GST)

Stage 2. Protein Glycan Coupling Technology (bioconjugation)

PGCT allows the bioconjugation of selected glycans to chosen acceptor proteins




Recombinant approach in *E. coli* - one step purification procedure

Flexibility of mixing & matching of protein/glycan combinations

Current status - producing an inexpensive recombinant glycoconjugate vaccine in 3 easy steps

1. DNA synthesise target protein with glycotags and target glycan
2. Add DNA encoding protein and glycan to *E. coli* cells expressing coupling enzyme on chromosome
3. Grow *E. coli* and purify vaccine from column



Simple process – *E. coli* is a mini factory

Current recombinant glycoconjugate vaccines

1. Improving existing glycoconjugate vaccines

Eg Streptococcus pneumoniae

2. New vaccines

Eg Francisella tularensis, Burkholderia pseudomallei, Coxiella burnetii, Clostridium difficile, Brucella species, Group A Strep, Shigella species, para typhi and Traveller's diarrhea

3. New markets



Eg Poultry and pig glycoconjugate vaccines

Glycoconjugate vaccine have not been used in animals?



Glycoengineering for veterinary vaccines

- 1. Triple poultry vaccine** – *Campy* glycan coupled to *perfringens* protein in attenuated *E. coli* or *Salmonella* strain



Glycoengineering for veterinary vaccines

- 2. Dual pig vaccine** – *Strep suis* capsule coupled to *Actinobacillus pleuropneumoniae* toxin
- 3. Dual bovine vaccine** – *Coxiella* O-antigen coupled to epsilon *perfringens* toxin?

Or Brucella O-antigen coupled to *Coxiella* carrier protein candidate

BBSRC £5 million multicentre Lola grant

LSHTM spin out – ArcVax (animal vaccines)

Conclusions and future perspectives

Basic curiosity driven research can lead to practical applications

- 1. In-exhaustible and homogeneous supply of vaccine – low cost**
- 2. Versatile technology - coupling glycans with carrier proteins**
- 3. “Double-hit” vaccines (eg *S. suis* protein with *S. suis* capsule)**
- 4. Piggy back onto existing attenuated vaccines for multiple protection**
- 5. Animal vaccines, not just for animal health & economic prosperity, but blocking zoonotic infections reduces human disease (One Health)**
- 6. Better vaccines (humans and animals), less antibiotic use**

Glycobod team

What makes a good carrier protein?

How to upscale and manufacture glycoconjugates?

Develop the E. coli glycozell to express diverse glycan?

What makes a good glycoconjugate vaccine?

